Healthcare

Intravenous Solutions Market 2024 | Market Size, Share Analysis, Demand And Forecast To 2033 | Pfizer Inc., Abbott Laboratories, Eli Lilly and Company, Fresenius SE & Co. KGaA, Becton

The Intravenous Solutions Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Intravenous Solutions Market:
https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

According to The Business Research Company’s Intravenous Solutions Global Market Report 2024, The intravenous solutions market size has grown strongly in recent years. It will grow from $12.9 billion in 2023 to $14 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rise in surgical procedures, growing prevalence of chronic diseases, expansion of home healthcare, stringent regulations ensuring product safety, increased focus on patient hydration, global emergency preparedness initiatives..

The intravenous solutions market size is expected to see strong growth in the next few years. It will grow to $18.95 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to population growth and aging, increasing surgical interventions, rising incidence of infectious diseases, telemedicine and remote patient monitoring, focus on preventive healthcare, global health security investments, patient-centric care trends.. Major trends in the forecast period include increased demand for parenteral nutrition solutions, rise in adoption of pre-mixed iv solutions, expansion of home infusion therapies, introduction of electrolyte-balanced solutions, introduction of novel drug additives and adjuncts, integration of smart iv systems for monitoring. .

The increasing prevalence of cancer is expected to propel the growth of the intravenous solutions market going forward. Cancer is a group of diseases characterized by uncontrolled cell growth and the ability to invade surrounding tissues and spread to other parts of the body. Intravenous solutions are commonly used in cancer treatment to deliver chemotherapy drugs and maintain hydration during therapy. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, around 1.9 million new cancer cases are expected to be diagnosed in the US, an increase from 1.8 million new cancer cases diagnosed in 2020. Further, in the US, 609,820 cancer-related deaths are anticipated in 2023, an increase from 606,520 in 2020. Therefore, the increasing prevalence of cancer is driving the growth of the intravenous solutions market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13465&type=smp

The intravenous solutions market covered in this report is segmented –
1) Intravenous Solutions Market By Product: Total Parenteral Nutrition, Peripheral Parenteral Nutrition
2) Intravenous Solutions Market By Nutrients: Carbohydrates, Vitamins And Minerals, Single Dose Amino Acids, Parenteral Lipid Emulsion, Other Nutrients
3) Intravenous Solutions Market By Application: Basic Intravenous (IV) Solution, Nutritional Intravenous (IV) Solution, Blood Intravenous (IV) Solution, Drug Intravenous (IV) Solution, Irrigation Intravenous (IV) Solution
4) By End User: Hospitals, Clinics, Ambulatory Surgery Centers, Home Care Settings

Top Major Players

Pfizer Inc.

Abbott Laboratories

Eli Lilly and Company

Fresenius SE & Co

KGaA, Becton

Major companies operating in the intravenous solutions market are focused on developing innovative syringes, such as pre-filled and ready-to-administer syringes, to gain a competitive edge in the market. Pre-filled and ready-to-administer syringes are preloaded with medication and designed for immediate use without requiring manual filling or preparation. For instance, in August 2023, GENIXUS Corp., a US-based healthcare company, launched KinetiXTM Rocuronium Bromide Injection in 5 mL and 10 mL ready-to-administer (RTA) syringes. The syringes are made of a transparent, durable polymer material that eliminates the risks associated with glass syringes. The syringes are pre-filled and ready to administer, saving time and reducing medication errors. Rocuronium bromide injection is for intravenous use only. It possesses several vital attributes, including RFID-enabled with KitCheck, the latest kit and tray management technology, intuitive labeling, and a color-coded plunger rod to support rapid identification.

The intravenous solutions market report table of contents includes:

1. Executive Summary

2. Intravenous Solutions Market Characteristics

3. Intravenous Solutions Market Trends And Strategies

4. Intravenous Solutions Market – Macro Economic Scenario

5. Global Intravenous Solutions Market Size and Growth

…..

32. Global Intravenous Solutions Market Competitive Benchmarking

33. Global Intravenous Solutions Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Intravenous Solutions Market

35. Intravenous Solutions Market Future Outlook and Potential Analysis

36. Appendix